News | February 10, 2024
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Distributes Ayushman cards to several beneficiaries
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Public private partnership (PPP) with integrated strategy essential to achieve ‘TB Mukt Bharat’ by 2025
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
